Shares of medical device makers like Davita and Baxter International plunged after Novo Nordisk said its GLP-1 drug Ozempic had some positive results in trials against kidney failure. So what could the impact be of a potential do-it-all drug? We surround the trade with Dr. Kavita Patel and Mizuho’s Jared Holz.
Fast Money Disclaimer
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
CNBC's "Fast Money"